204 related articles for article (PubMed ID: 38711203)
1. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
2. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.
Fourneaux B; Bourdon A; Dadone B; Lucchesi C; Daigle SR; Richard E; Laroche-Clary A; Le Loarer F; Italiano A
J Hematol Oncol; 2019 Jan; 12(1):11. PubMed ID: 30683135
[TBL] [Abstract][Full Text] [Related]
3. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer.
Zhu S; Ma AH; Zhu Z; Adib E; Rao T; Li N; Ni K; Chittepu VCSR; Prabhala R; Garisto Risco J; Kwiatkowski D; Mouw K; Sonpavde G; Cheng F; Pan CX
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725212
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Yan C; Yang J; Saleh N; Chen SC; Ayers GD; Abramson VG; Mayer IA; Richmond A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069042
[TBL] [Abstract][Full Text] [Related]
6. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
[TBL] [Abstract][Full Text] [Related]
9. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
10. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
11. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
13. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
[TBL] [Abstract][Full Text] [Related]
17. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
18. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
